Search the Newsreel

Boston Scientific stock holds gains as cardiovascular revenue grows and new devices support long ter

Boston Scientific's stock stability is attributed to its cardiovascular and MedSurg portfolio expansion, marked by increased revenue and better margins from new devices. The company's focus on minimally invasive medical devices and robust revenue growth supports its market position, with significant investment in R&D …

Boston Scientific Aktie: Wachstumsziel auf 7–8,5% gesenkt

Boston Scientific stock trades steady as latest earnings highlight growth and margin focus

Boston Scientific (NYSE: BSX) has demonstrated solid financial performance, with fiscal 2025 net sales reaching approximately $16.0 billion, a 10% increase from 2024, driven by strong growth in its Cardiovascular and MedSurg segments. The company's operating income also saw significant growth, rising around 20% …

Boston Scientific stock trades steady as cardiovascular and neuromodulation growth supports earnings

Boston Scientific's stock is supported by robust growth in its cardiovascular and neuromodulation divisions, demonstrating double-digit revenue expansion and improved margins. The company benefits from a diversified product portfolio, ongoing innovation in minimally invasive therapies, and strategic geographic expansion. These factors, alongside disciplined cost …

Boston Scientific Corp. stock underperforms Friday when compared to competitors

Boston Scientific Corp. (BSX) stock fell by 1.32% on Friday, closing at $44.03, underperforming its competitors and the broader market. This decline occurred during a generally negative trading session, with the S&P 500 Index dropping 1.01% and the Dow Jones Industrial Average falling 0.77%. …

Boston Scientific stock trades steadily as Q1 2026 growth and cardiology portfolio underpin valuatio

Boston Scientific's stock is trading steadily, supported by strong Q1 2026 revenue growth and expanding margins across its medical technology portfolio. The company's focus on interventional cardiology, structural heart treatments, and minimally invasive technologies, particularly with products like the WATCHMAN device, underpins its valuation …

Boston Scientific Expands Medical Device R&D in Ireland With €75 Million Investment

Boston Scientific is investing €75 million to expand its research and development capabilities at its Galway facility in Ireland. This investment will enhance the site's role in developing next-generation cardiovascular and medical technologies, including new laboratories. The expansion aims to accelerate the development of …

Boston Scientific stock hits 52-week low at 42.24 USD By Investing.com

Boston Scientific's stock has fallen to a 52-week low of $42.24, despite an InvestingPro analysis suggesting it is undervalued with "GREAT" financial health and 17% revenue growth. This downturn follows lowered price targets from several analyst firms due to anticipated slowdowns in WATCHMAN device …

Boston Scientific Aktie: 77 auf 57 Dollar – WATCHMAN belastet

Boston Scientific Aktie: Watchman bremst Wachstum

Boston Scientific Aktie: FDA stuft Orca-Ventile als Class II ein

Boston Scientific Aktie: 65% Kurspotenzial trotz anhaltender Talfahrt

Aktie von Boston Scientific fällt um 10 % – Schwäche bei Watchman-Implantaten und Wettbewerbsdruck belasten

Boston Scientific Aktie: 2 Milliarden Dollar Rückkauf mit JPMorgan

Boston Scientific Stock Near 52-Week Lows: Why Analysts Still See a 60% Upside for 2026

We're Not Worried About Belo Sun Mining's (TSE:BSX) Cash Burn

Boston Scientific Stock: Is the EP Share Loss Fear Creating a 60% Mispricing Right Now?

Boston Scientific-Aktie: Solide Zahlen, schwacher Ausblick!

Boston Scientific Fell 28% in 2026, Do Analysts See Recovery?

Boston Scientific-Aktie: Ist die Wachstumsstory vorbei?

Down 10% In Last 12 Months, Can Boston Scientific Stock Recover Through 2027?

Boston Scientific Stock Prediction: Where Analysts See the Stock Going by 2027

Belo Sun Mining (BSX) Stock Price, News & Analysis $BSX